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Abstract
Functionalized polymeric nanocarriers have been recognized as drug delivery platforms for 
delivering therapeutic concentrations of chemotherapies. Of this category, star-shaped multiarm 
polymers are emerging candidates for targeted delivery of anti-cancer drugs, due to their compact 
structure, narrow size distribution, large surface area and high water solubility. In this study, we 
synthesized a multi-arm poly(acrylic acid) star polymer via MADIX/RAFT polymerization and 
characterized it using NMR and size exclusion chromatography. The poly(acrylic acid) star 
polymer demonstrated excellent water solubility and extremely low viscosity, making it highly 
suited for targeted drug delivery. Subsequently, we selected a hydrophilic drug, cisplatin, and a 
hydrophobic nitric oxide-donating prodrug, O2-(2,4-dinitrophenyl) 1-[4-(2-hydroxy)ethyl]-3-
methylpiperazin-1-yl]diazen-1-ium-1,2-diolate, as two model compounds to evaluate the 
feasibility of using poly(acrylic acid) star polymers for delivery of chemotherapeutics. After 
synthesizing and characterizing two poly(acrylic acid) star polymer-based nanoconjugates, 
poly(acrylic acid)-cisplatin (acid-Pt) and poly(acrylic acid)-nitric oxide prodrug (acid-NO), the in 
vitro drug release kinetics of both acid-Pt and acid-NO were determined at physiological 
conditions. In summary, we have designed and evaluated a polymeric nanocarrier for sustained-
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We successfully developed multi-arm, star-shaped polymeric carriers for the delivery of nitric 
oxide-donating prodrugs and cisplatin. The carriers release nitric oxide prodrugs or cisplatin in a 
sustained fashion, inhibiting the growth of cancer cells in vitro.
Keywords
Conjugated polymer; drug delivery systems; reversible addition fragmentation chain transfer 
(RAFT); star polymer; water-soluble polymer
Introduction
Star polymer architectures are a new generation of branched polymeric materials that consist 
of a single core and multiple connecting arms or chains. Star polymers usually have highly 
condensed and globular structures, tailorable size and large surface areas for conjugation of 
drugs and imaging agents, which makes them suited as potential delivery platforms. Various 
star polymer carriers have been synthesized and utilized for the delivery of small-molecule 
chemotherapeutics, including doxorubicin 1 (conjugation) and paclitaxel 2 (encapsulation), 
proteins, such as insulin 3, as well as genetic materials, such as DNAs 4 and siRNAs 5. 
Herein, we developed a multi-arm poly(acrylic acid) star polymer (Fig. 1) via MADIX/
RAFT polymerization for long sustained release of multiple chemotherapeutics 
simultaneously as a chemo ‘cocktail’.
Cisplatin is a water soluble, platinum-based chemotherapeutic that has been widely used for 
many years in the clinic as a first-line chemotherapy for head and neck squamous cell 
carcinoma, ovarian cancer, and non-small cell lung cancer. The major side effect of cisplatin 
infusion chemotherapy is renal toxicity, which limits its use. The toxicity of cisplatin is 
dependent on the maximum concentration of free drug in the plasma. Slow and confined 
release of cisplatin into tumors can largely alleviate these toxicities. In our previous studies, 
we synthesized a hyaluronan-cisplatin conjugate for the controlled release of subcutaneously 
delivered cisplatin using the biodegradable and biocompatible polymer hyaluronan 6. The 
conjugates achieved superior pharmacokinetics, reduced systemic toxicity, and enhanced 
anti-cancer efficacy in rodents compared to unbound intravenous cisplatin 7–10. However, a 
major drawback of this hyaluronan-based delivery platform and other linear polymers is the 
relatively high intrinsic viscosity of the vehicle, which makes it challenging to administer a 
high concentration of the chemotherapy within a small injection volume. Therefore, we 
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sought to develop another drug carrier with desired solubility and viscosity characteristics 
that could sustain cisplatin over several days.
Polymer carriers can overcome problems with drug solubility and stability. We have 
developed a nitric oxide-donating prodrug, similar to other drugs in this class, it releases 
nitric oxide (NO) in vivo upon activation by glutathione-s-transferase in cells. But it is both 
very poorly water soluble and unstable in serum. Nitric oxide has been shown to effectively 
inhibit the proliferation of many cancer cells, including breast cancer 11, colon cancer 12, 
non-small cell lung cancer 13, and melanoma 14. It is a gaseous small molecule with a half 
life of only seconds 15. To deliver therapeutic concentrations of nitric oxide to tumorigenic 
tissues, a controlled release strategy is critical. A number of sustained release carriers have 
been designed for the delivery of nitric oxide, including NO-donor incorporated ethylene/
vinyl acetate polymers 16, S-nitrosothiol conjugated interpolymers 17, as well as block 
copolymer of N-acryloylmorpholine and N-acryloyl-2, 5-dimethylpiperazine 18. To date, no 
combinational NO/cisplatin delivery platforms have been developed for delivering these two 
chemotherapeutics simultaneously. Therefore, we designed a nanocarrier-based system to 
generate active nitric oxide molecules and DNA-crosslinking platinum in a sustained release 
manner that maintains a relatively steady level of NO and platinum within the therapeutic 
window for a longer period of time during treatment.
Experimental
Materials
Unless noted otherwise, all reagents and solvents were purchased from Sigma Aldrich (St 
Louis, MO) or Fisher Scientific (Pittsburgh, PA) and used without further purification. 1H-
NMR (400 MHz) and 13C-NMR (100 MHz) spectra were collected on a Bruker DRX 400 
spectrometer using compounds dissolved in CDCl3, MeOD or D2O. Chemical shifts were 
referenced to δ7.28 and 77.0 ppm for 1H-NMR and 13C-NMR spectra, respectively. High-
resolution mass spectrometry (HRMS) data were generated after flow injection analysis 
(FIA) and manually matching peaks on an Applied Biosystems Mariner TOF spectrometer 
with a turbo-ionspray source. The cell culture media were purchased from MediaTech Inc 
(Manassas, VA).
Synthesis
Synthesis of MADIX/RAFT agent—The MADIX/RAFT agent was synthesized based 
on the procedure reported previously (Fig. 2) 19. The core starting material, pentaerythritol, 
was esterified with 2-bromopropionyl bromide and O-ethylxanthic acid (potassium salt), 
successively, to form a four-arm sulfur compound that was used as the MADIX/RAFT 
initiator agent.
4-arm core initiator 1: Pentaerithol (1.36 g, 10 mmol) was dissolved in dry chloroform (25 
mL) and pyridine (2.5 mL) and cooled to 0 °C. The 2-bromo propionyl bromide (10.01 g, 45 
mmol) was added dropwise, and the reaction proceeded at ambient temperature (ca. 23°C) 
for 48 hours. The mixture then was neutralized with aqueous HCl (10 wt %). Then the 
organic phases were washed with water, sodium bicarbonate solution (5%) and then brine, 
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followed by drying with sodium sulfate. The solvent was evaporated under reduced 
pressure, which yielded the desired compound. The molecular structure was verified by 1H-
NMR and compared with the reported data.
A solution of the intermediate compound (2.028 g, 3.0 mmol) in chloroform (45 mL) was 
treated with a 10-fold excess of O-ethylxanthic acid, potassium salt (5.01 g, 30 mmol). The 
mixture was stirred at ambient temperature for 3 days, and the resulting suspension was 
filtered and washed with chloroform. Evaporation of the solvent followed by purification 
through a flash column on silica gel using 3:7 ethyl acetate:hexanes as eluents yielded the 
desired compound, and the molecular structure was verified by 1H-NMR and compared with 
the reported data.
Synthesis of 4-arm tert-butyl acrylate star polymer—The multiarm tert-butyl 
acrylate star polymer was synthesized based on a modification of Ting et al.’s procedure 20. 
The tert-butyl acrylate (2.50 g, 19.5 mmol) was treated with basic alumina and dry α, α, α-
trifluorotoluene (10 mL) in a 50-mL round bottom flask. The RAFT agent 1 (27 mg, 
3.25×10−2 mmol) was added to the solution, followed by the addition of AIBN (0.53 mg, 
3.25×10−3 mmol), and the reaction flask was placed on ice and purged with argon for 30 
min. The flask then was transferred to a thermostatic oil bath at 70 °C for ca. 12 hours. The 
mixture was cooled in an ice bath and poured into cold diethyl ether to obtain the precipitate 
followed by concentration under reduced pressure (Fig. 3). The molecular structure and 
molecular weight of the resulting polymer were determined by 1H-NMR and size exclusion 
chromatography (SEC), respectively.
Synthesis of multiarm acrylic acid star polymers—The tert-butyl acrylate star 
polymer (2.50 g, 19.5 mmol) was dissolved in dichloromethane (200 mL), and 
trifluoroacetic acid (TFA, 75 mL, 975 mmol) was then added. The mixture was stirred 
vigorously until the generation of white precipitate ceased. The precipitate was filtered and 
washed with dichloromethane and diethyl ether, and then dried under reduced pressure 
overnight. The molecular structures and weights of the resulting polymers (Fig. 4) were 
determined by 1H-NMR and SEC, respectively.
Synthesis of poly(acrylic acid) star polymer-cisplatin conjugates—The 
poly(acrylic acid) star polymer-cisplatin conjugates (acid-Pt) were synthesized according to 
the procedure of Cai et al.6. Poly(acrylic acid) star polymer (50 mg) was dissolved in dd 
H2O (25 mL) in a 50-mL round bottom flask. The pH of the solution was adjusted to 10 
using 1-M NaOH solution and cisplatin (25 mg) was added. The solution was stirred under 
argon protection at ambient temperature for 36 hours. The solution then was dialyzed (10-
kDa MWCO tubing, Pierce, Rockford, IL) against distilled water at 4 °C for 2 days with 
water changes every 6 hours to remove the unbound cisplatin. After dialysis the resulting 
polymer was concentrated by rotary evaporation to obtain the desired multi-arm poly(acrylic 
acid) star polymer-cisplatin conjugates (Fig. 5).
Synthesis of a nitric oxide-donating prodrug, O2-(2,4-Dinitrophenyl) 1-{[4-(2-
(2-hydroxyethoxy))ethyl] piperazin-1-yl}diazen-1-ium-1,2-diolate—The nitric 
oxide prodrug was synthesized according to the procedure of Chakrapani et al 21 (Fig. 6). 
Duan et al. Page 4













The 1-[2-(2-hydroxyethoxy)ethyl]piperazine (5.0 g, 27.3 mmol) was dissolved in methanol 
(2 mL) and treated with 25% w/v methanolic sodium methoxide (6.2 mL) and ether (20 
mL). The resulting solution was charged with NO at 60 psi and stirred at ambient 
temperature for 24 hours, leading to the formation of a white precipitate. The white solid 
was filtered, washed with ether, and dried under reduced pressure to afford the sodium 1-[2-
(2-hydroxyethoxy)ethyl] homopiperazin-1-yl] diazen-1-ium-1, 2-diolate. Subsequently, the 
white solid was dissolved in 5% w/v ice cold sodium bicarbonate solution (60 mL). The 
solution was treated with 1-fluoro-2,4-dinitrobenzene (4.67 g, 25.1 mmol) pre-dissolved in a 
mixture of t-BuOH (30 mL ) and THF (5 mL). A yellow precipitate formed immediately and 
was purified by silica flash chromatography (CHCl3: EtOAc=9:1) to afford the desired 
compound. The molecular structure was verified by 1H-NMR and mass spectrometry.
Synthesis of poly(acrylic acid) star polymer-nitric oxide prodrug conjugates—
The poly(acrylic acid) star polymer (50 mg) was dissolved in 25 mL of ice cold DMF: dd 
H2O (25:1 v/v) mixture in a 50-mL round bottom flask (Fig. 7), and EDCI·HCl (1.5 eq) and 
HOBt·H2O (1.5 eq) were added to the solution. After 5 minutes, O2-(2,4-Dinitrophenyl) 1-
{[4-(2-(2-hydroxyethoxy))ethyl] piperazin-1-yl}diazen-1-ium-1,2-diolate (1.0 eq) was added 
to the solution. The reaction proceeded under argon at 0 °C for 30 minutes, followed by 
ambient temperature overnight in the dark. The resulting acid-NO conjugate was dialyzed 
using 10,000 MWCO tubing against a mixture of dd H2O: ethanol (1:1 v/v) at ambient 
temperature for 12 hours, followed by ethanol for another 12 hours. The desired acid-NO 
conjugates were obtained after the evaporation of the solvent under reduced pressure. The 
molecular structure was verified by 1H-NMR.
Characterization
Size exclusion chromatography—The molecular weights and polydispersity index 
(PDI) of the multi-arm tert-butyl acrylate star polymers were determined using EZStart 7.4 
software and a Shimadzu 2010CHT system equipped with a RID-10A refractive index 
detector and a TSK gel multipore Hx-M 7.8×30 cm column using 10-mM LiCl in DMF (0.8 
mL/min) as the mobile phase. The calibration curve was generated using polystyrene 
standards ranging from 1,180 to 339,500 g/mol. After deprotection, the resulting multi-arm 
poly(acrylic acid) star polymer was highly soluble in methanol, water, DMF, and DMSO. 
The molecular weights of the multi-arm poly(acrylic acid) star polymers were determined by 
SEC using polyethylene glycol (PEG) standards ranging from 3,070 to 66,100 g/mol 
(Scientific Polymer Products, Inc) (Table 1).
Determination of drug conjugation—The substitution degree of the NO prodrug on the 
acid-NO conjugate was determined by 1H-NMR based on the ratio of the aromatic protons 
of the NO prodrug to the methylene protons of the polymer core. The degree of cisplatin 
substitution was determined by atomic absorption spectroscopy (AAS) (Varian SpectrAA 
GTA-110 with graphite furnace) using platinum standards ranging from 100 to 450 ppb 
(Fisher Scientific) 6. The furnace program was as follows: ramp from 25 to 80°C, hold 2 s, 
ramp to 120°C, hold 10 s, ramp to 1000°C, hold 5 s, ramp to 2700°C, hold 2 s, cool to 25°C 
over 20 s. The graphite partition tube was cleaned every 40 samples by baking at 2800°C for 
7 s. Argon was used as the injection and carrier gas.
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Viscosity—The viscosity parameters were measured using a Stabinger viscometer (SVM 
3000, Anton Paar, USA). A series of multi-arm poly(acrylic acid) star polymer samples 
(MW: 64,000; 75,000; 803, 00; 110,000 g/mol) were prepared by dissolving the polymers in 
dd H2O at three concentrations including: 1.0 mg/mL, 3.0 mg/mL and 10.0 mg/mL.
In vitro release of drug from acid star polymers—The in vitro release kinetics of 
cisplatin was determined according to our previously published procedure 6. The acid-Pt 
conjugate (10 mg) was dissolved in PBS (10 mL), transferred to dialysis tubing (10,000 Da 
MWCO), and placed in a PBS bath (pH 7.4, 37 °C, 4 L) with or without 10% bovine serum 
albumin and 0.2% sodium azide. Two hundred microliter aliquots were collected from the 
tubing at pre-determined intervals and stored at −80 °C until analysis by AAS. The AAS 
produced a linear concentration curve from 10 to 450 ng/mL (R2=0.9998), with a limit of 
detection of 5 ng/mL and a limit of quantification of 10 ng/mL (5% standard deviation).
The release half-life of nitric oxide from NO-prodrug and acid-NO conjugates was 
determined in cell culture. MCF-7 cells were seeded in 96-well plates 24 hours prior to drug 
treatment (100 μL/well). On the following day, cells were treated with 20 μM of either the 
nitric oxide prodrug or the multi-arm polymer based nitric oxide prodrug conjugate, acid-
NO. Fifty microliters of cell culture media were collected from each plate at 10 minutes, 2, 
7, 22, 48 and 96 hours, post treatment to determine the nitrite content (N=5). The Griess 
reaction was performed according to the manufacturer’s protocol. The absorbance was 
measured at 535 nm using a UV microplate reader. The nitrite concentration and the 
corresponding nitrite oxide levels were determined using the nitrite standard curve 
previously generated.
Cytotoxicity—Cell growth inhibition was determined in 96-well plates. Plates were seeded 
with 3,000 cells/well in 100 μL of media (12 replicates/sample). Drug or conjugate solutions 
were applied after 24 hours. Resazurin blue in 10 μL of PBS was applied to each well (final 
concentration 5 μM) after another 72 hours. After 4 hours, the well fluorescence was 
measured (ex/em 560/590) (SpectraMax Gemini, Molecular Devices), and the IC50 
concentration was determined as the midpoint between drug-free medium (positive) and 
cell-free (negative) controls.
Results and Discussion
Synthesis of acid-NO and acid-Pt conjugates
The poly (tert-butyl acrylate) star polymers were synthesized via MADIX/RAFT 
polymerization mediated by xanthates in α, α, α-trifluorotoluene, using AIBN as an 
initiator. The MADIX/RAFT polymerization approach is of special interest to polymer and 
drug delivery scientists compared to other synthetic strategies involving free radical 
reactions, including NMP, ATRP, and RAFT, as a wide range of potential monomers could 
be readily utilized to generate well-controlled polymeric architectures. The polymerization 
resulted in 90 % conversion of the monomers after a reaction duration of approximately 14 
hours. Reaction byproducts started to form if the reaction was allowed to proceed for longer 
than 20 hours. Subsequent treatment of the poly (tert-butyl acrylate) star polymers of 
different molecular weights with TFA acid in dichloromethane yielded the corresponding 
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acid star polymers. The acid star polymer and its corresponding polymer-chemotherapeutic 
conjugates, including acid star polymer-nitric oxide prodrug conjugate (20% wt drug 
loading) and acid star polymer-cisplatin conjugates (8% wt drug loading) were successfully 
synthesized. The acid star polymers were soluble in water, methanol, DMF and DMSO. 
Besides the multi-arm poly(acrylic acid) star polymers we developed, various other 
polymeric systems have also been explored for locoregional delivery of anti-cancer drugs, 
including PEG-graft-α,β-poly [(N-amino acidyl)-aspartamide] polymers 22, PLGA-4-arm-
PEG branched polymeric nanoparticles 23, and a core-shell star polymer carrier with a 
poly(styrene) core 24.
Characterization – size exclusion chromatography
The molecular weights of the poly (tert-butyl acrylate) star polymers and their 
corresponding acid star polymers were determined by SEC using polystyrene and 
polyethylene glycol (PEG) as standards, respectively (Fig. 8). The PDIs of poly (tert-butyl 
acrylate) star polymer and acid star polymer with increasing molecular weights were 
calculated and reported in Table 1. The PDIs were similar to values reported by other groups 
using MADIX/RAFT to form structured polymers, including 4-arm star polymers reported 
by Stenzel and coworkers (PDIs: 1.20 to 1.44) 19. The PDI was in part due to using linear 
PEGs and polystyrenes as molecular weight standards, since standards with similar 
architecture were not available. Also, the highly charged nature of the polymers may have 
led to some interactions with the column stationary phase.
Characterization – NMR
The molecular structures of the star polymers and nitric oxide prodrug were verified 
using 1H-NMR, 13C-NMR and HR-MS (Fig. 9). All data were consistent with the published 
results (purity>99%).
O2-(2,4-Dinitrophenyl) 1-{[4-(2-(2-hydroxyethoxy))ethyl] piperazin-1-
yl}diazen-1-ium-1,2-diolate—1H-NMR (CDCl3, 400 MHz): δ = 1.69 (brs, 1H), 2.70 (t, J 
= 5.3 Hz, 2H), 2.80 (t, J = 5.1 Hz, 4H), 3.63–3.66 (m, 2H), 3.69–3.75 (m, 8H), 7.68 (d, J = 
9.3 Hz, 1H). 8.47 (dd, J = 9.2, 2.7 Hz, 1H), 8.90 (d, J = 2.7 Hz, 1H); 13C-NMR (CDCl3, 100 
MHz): δ = 50.3, 51.5, 57.0, 61.9, 68.0, 72.3, 117.6, 122.2, 129.1, 137.2, 142.3, 153.9. 
HRMS (ESI) Calculated for C14H21N6O8 (M + H) +: 401.1421; Found: 401.1413.
Poly (tert-butyl acrylate) star polymer—1H-NMR (CDCl3, 400 MHz): δ = 4.65 (q, 
8H), 4.25 (q, 4H), 4.03 (q, 8H), 2.25 (brs), 1.86 (brs), 1.65–1.27 (brs, overlap).
Poly(acrylic acid) star polymer—1H-NMR (CDCl3, 400 MHz): δ = 4.66 (q, 8H), 4.30 
(q, 4H), 4.14 (q, 8H), 2.25 (brs), 1.86 (brs), 1.65–1.27 (brs, overlap), 1.30 (t, 12H).
Poly(acrylic acid) star polymer-nitric oxide prodrug conjugate—1H-NMR 
(CDCl3, 400 MHz): δ = 8.90 (d, J = 8.4 Hz, 1H), 8.57 (dd, J = 8.4 Hz, 1H), 7.68 (d, J = 13.2 
Hz, 1H), 4.66 (q, 8H), 4.30 (q, 4H), 4.14 (q, 8H), 3.73 (m, 8H), 3.65 (m, 2H), 2.79 (m 4H), 
2.70 (m, 2H), 2.73 (brs), 1.81–1.48 (brs, overlap).
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Poly(acrylic acid) star polymer-cisplatin conjugate—1H-NMR (CDCl3, 400MHz): 
δ= 4.68 (q, 8H), 4.38 (q, 4H), 2.55–2.37 (bs), 2.06–1.89 (bs), 1.84–1.66 (bs), 1.44 (t, 3H), 
1.20 (d, 3H).
Characterization – viscosity
The viscosity of acid star polymers slightly increased with increases in either the molecular 
weight (54.0 to 110.7 kDa) or the concentration (1 to 10 mg/mL) of the polymer (Fig. 10). 
The viscosity of the acid-NO conjugates was also evaluated and compared to the acid star 
polymer itself at three different concentrations. The acid star polymer selected for the drug 
conjugation had a molecular weight of 72.3 kD. Based on our ongoing studies, star polymers 
with a molecular weight close to 75 kD exhibit advantageous patterns of lymphatic drainage 
and retention, compared to star polymers of higher or lower molecular weights, thus, the 
72.3-kD star polymer drug carrier may be a potential candidate for localized drug delivery 
applications. It is worth noting that none of the acid star polymers tested exhibited high 
viscosity compared to other polymeric injectables for localized drug delivery, including 
hyaluronic acid, which demonstrated a 3-fold increase in viscosity relative to acid star 
polymers with a similar molecular weight at 10 mg/mL (data not shown). The FDA 
recommends that injectables have a viscosity of less than 50 cP, which may be readily 
injected using a 25- or 27-ga needle. The viscosities of our materials were less than 2 cP, 
and they can be easily injected using a 31-ga needle. Thus, these polymers are highly suited 
for a locally administered chemotherapeutics due to their low viscosity at high 
concentrations, which allows the use of small-bore needles and low injection volumes.
In vitro release of platinum from acid-Pt
The release kinetics of cisplatin from the acid star polymer backbone was determined in 
PBS (pH 7.4) at 37°C with or without 10% serum. The half-life was determined by fitting 
the release data to either a zero order linear regression model (release of Pt in PBS without 
serum) or a first order decay model (release of Pt in serum-containing PBS) using GraphPad 
5 (R2 >0.97 for all fits). The acid-Pt conjugates demonstrated an extended shelf-life in PBS 
with a platinum release half-life of approximately 120 days (Fig. 11A), which is 
significantly more stable than other sustained delivery platforms of cisplatin, including 
cisplatin-incorporating polymeric micelles (release half-life: ca. 4 days) 25, and dextran-
based cisplatin conjugates (release half-life: ca. 2 days) 26. The presence of serum expedited 
the drug release from the acid polymers, which is likely due to the competitive binding 
between the platinum and the proteins present in the serum. The conjugates were able to 
sustain the release of cisplatin over 9 days (95% complete) with a release half-life of 
approximately 36.7 hours in serum-containing PBS (Fig. 11B), suggesting satisfactory 
stability in plasma in vivo. If this delivery platform could be translated into the clinic, it may 
be utilized as an adjuvant or maintenance chemotherapy post-surgery, releasing a steady 
concentration of platinum for an extended period of time, which may eradicate the residual 
disease and potential nano- or micro-metastases in the surrounding tissues and draining 
lymph nodes.
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In vitro release of NO from acid-NO
The release kinetics of nitric oxide from both the prodrug (NO-prodrug) and the carrier-
nitric oxide prodrug conjugate (acid-NO) were determined in cell culture media. The half-
lives were determined be 7.4 and 5.3 hours for NO-prodrug and acid-NO, respectively, by 
fitting the release data to a first order decay model using GraphPad 5 (R2 >0.97 for all fits, 
Table 2). The acid-NO exhibited a shorter release half-life compared to the NO-prodrug, 
which is largely due to the initial burst release of NO (Fig. 12). The poly(acrylic acid) star 
polymer backbone created a more acidic microenvironment surrounding the conjugates once 
they were solubilized in cell culture media, which triggered the liberation of NO 
immediately. Without the burst release, the acid-NO demonstrated a similar t1/2 as the NO-
prodrug. Another NO-donating prodrug in preclinical studies, JS-K 11,27,28, has a NO 
release half-life of approximately 3.2 hours (data not shown), which is shorter than the 
release t1/2 of either the NO-prodrug or the acid-NO. All of the aforementioned NO-
prodrugs tested exhibited significantly longer half-lives of NO release compared to the 
gaseous nitric oxide, which has a t1/2 of 0.05 to 0.18 milliseconds in blood 29. According to 
Fetz et al, pretreatment of head and neck cancer cells using NO-donors, including S-nitroso-
N-acetyl-penicillamine (SNAP), reverted the cells’ cisplatin resistance via the modulation of 
survivin30. Thus, a drug delivery platform that generates fast-releasing nitric oxide, along 
with slow-releasing platinum, may be a potential candidate for the delivery of synergistic 
cisplatin and nitric oxide combination chemotherapy.
Cytotoxicity of acid-NO and acid-Pt conjugates
The in vitro anti-proliferative activities of cisplatin, NO-donating prodrug, and their star 
polymer-based conjugates, including acid-Pt, acid-NO, and combinational acid-Pt/acid-NO 
were evaluated in cell culture using a human breast cancer cell line, MCF-7 (Table 2). Acid-
NO conjugates demonstrated a similar IC50 to the free NO-prodrug. Release of nitric oxide 
from the polymeric matrix inhibited the growth of cancer cells. The acid-Pt appeared to be 
less cytotoxic than cisplatin in the cells. This is likely due to the slow release of the active 
drug, which was not unexpected for a sustained-delivery platform. One of the obstacles that 
has not yet been overcome in infusion chemotherapy is the poor tumor penetration and 
accumulation of small-molecule anti-cancer agents. Usually the majority of the 
chemotherapeutics have been cleared from systemic circulation, via the kidneys, before a 
significant concentration of the anti-cancer agent is achieved in the tumorigenic tissues. 
However, the acid-Pt and acid-NO nanoconjugates may greatly enhance the intratumoral 
drug concentration compared to the normal tissues due to the Enhanced Permeability and 
Retention effect (EPR), in which nanoformulations tend to penetrate tumors more 
effectively via leaky, fenestrated tumor blood vessels. In addition, the acid-Pt and acid-NO 
formulations could be given subcutaneously as a local injection adjacent to the tumor to 
eradicate potential metastasis in the tumor-draining lymph nodes; whereas, it is clinically 
infeasible to inject free cisplatin or nitric oxide subcutaneously due to the severe tissue 
damage that the anti-cancer agents would create. After local injection of the acid-Pt, or the 
acid-NO, the nanocarriers diffuse into the surrounding cutaneous tissues and enter the 
lymphatic vessels filled with lymph fluid; subsequently, they follow the lymph and reach the 
sentinel lymph node, the first tumor draining lymph node, and deliver the chemotherapeutics 
to the metastases. Furthermore, both of the star polymer-based conjugates could be given 
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simultaneously as a localized combination therapy. Nitric oxide has been shown to 
overcome chemoresistance in a cisplatin-insensitive human head and neck squamous cell 
carcinoma cell line30. The concurrent administration of both the cisplatin- and NO-releasing 
conjugates may minimize the incidence of acquired chemoresistance during therapy and 
maximize the efficacy of the combination treatment. Similar to cisplatin, nitric oxide has 
also been found to sensitize cancer cells to ionizing radiation 31, which may be used as an 
adjuvant combination regimen post radiation therapy. In addition, nitric oxide was recently 
found to increase the anti-tumor activity of other chemotherapeutics, e.g. doxorubicin 32. 
This discovery can be further explored using a combinational polymer-based, sustained-
release doxorubicin (hyaluronan-doxorubicin) 33 and nitric oxide (acid-NO) delivery 
platform that our laboratory developed for treating cancers that are responsive to 
doxorubicin therapy, including certain types of breast, lung and ovarian cancers.
Conclusion
In summary, we have successfully synthesized a multi-arm poly(acrylic acid) star polymer 
architecture suited for the multimodal delivery of both hydrophilic and hydrophobic 
chemotherapeutics, as either a single-drug chemotherapy or a combinational regimen. This 
strategy has laid the foundation for future investigations of the delivery of chemo-cocktails 
using multiple anti-cancer agents that possess a synergism in vivo.
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Chemical structure of multiarm poly(acrylic acid) star polymer
Duan et al. Page 12














Synthesis of MADIX/RAFT agent
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Synthesis of multiarm tert-butyl acrylate star polymers
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Synthesis of multiarm acrylic acid star polymer from tert-acrylate star polymer
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Synthesis of poly(acrylic acid) star polymer-cisplatin conjugates
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Synthesis of O2-(2,4-Dinitrophenyl) 1-{[4-(2-(2-hydroxyethoxy))ethyl] piperazin-1-
yl}diazen-1-ium-1,2-diolate
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Synthesis of poly(acrylic acid) star polymer-nitric oxide prodrug conjugates
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SEC traces of poly(tert-butyl acrylate) star polymers (Left panel, MWs: 148,991, 115,697, 
and 93,891 Da) and poly(acrylic Acid) star polymers (Right panel, MWs: 86,073, 67,112, 
and 54,007 Da)
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1H-NMR spectra of poly (tert-butyl acrylate) star polymer (top panel, solvent: CDCl3), and 
poly(acrylic acid) star polymer (bottom panel, solvent: MeOD)
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Viscosity measurements of A) a poly(acrylic acid) star polymer at concentrations of 1, 3 and 
10 mg/mL, and B) a star polymer nitric oxide prodrug conjugate (acid-NO, 72.3 kDa)
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Release of platinum from acid-Pt conjugates in A) PBS, and B) PBS with 10% serum at 37 
°C (N=3). The release half-lives were determined to be 120 days and 36.7 hours, using a 
linear regression or a first order decay model in GrapPad 5, respectively.
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Release of nitric oxide from NO-prodrug and acid-Pt conjugates in cell culture media at 37 
°C (N=3). The half-lives were determined be 7.4 and 5.3 hours for NO-prodrug and acid-
NO, respectively, by fitting the release data to a first order decay model using GraphPad 5 
(R2 >0.97 for all fits).
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Table 2






Release half-life was determined in PBS with 10% serum at 37 °C.
*
Release half-lives were determined in cell culture media with MCF-7 cells.
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